We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, efficacy, Keytruda, outcome, pembrolizumab, safety, trial | 5 Comments »
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
An abstract that we missed at the ASCO meeting this year came to our attention when we read this article by Dr. Jeffrey Kirshner: “Ten practice changes I will make after attending ASCO 2017“. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, Larotrectinib, LOXO-101, safety | 5 Comments »
We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, Lu-177, mCRPC, PSMA, safety, Treatment, trial | 2 Comments »
In a newly published article on the STAT web site, two clinicians at Oregon Health and Science University argue that the benefits of immunotherapy in the treatment of cancer are being greatly over-“hyped”. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, hype, immunotherapy, safety | 2 Comments »
When Jeff Demanes at the California Endocurietherapy Center, then in Oakland, CA, started doing high-dose-rate brachytherapy (HDR-BT) as a monotherapy (i.e., without any additional external beam therapy or hormone therapy), he arbitrarily chose a treatment schedule of 42 Gy delivered in six treatments or fractions. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, efficacy, fractions, risk, side effects | 4 Comments »
New immunotherapeutic drugs known as PD-1 inhibitors (drugs like nivolumab/Optivo and pembrolizumab/Keytruda) have shown some remarkable effects in the treatment of advanced forms of cancer like melanoma and some forms of lung cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, efficacy, inhibitor, outcome, PD-1 | Leave a comment »
According to what appears to have been a pretty forthright presentation at the ongoing annual meeting of the American Society for Radiation Oncology (ASTRO), many commonly used men’s health and prostate supplements weren’t helping prostate cancer patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: efficacy, safety, supplement, value | 8 Comments »
Last Friday, the National Comprehensive Cancer Cancer Network (NCCN) introduced a new way for doctors and patients to be able to consider the clinical “value” of treatment with specific drugs in specific forms of cancer. How useful this method is will take a while to work out. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: affordability, efficacy, evidence, guideline, NCCN, safety, value | Leave a comment »
Sometimes, when patients originally present with very high PSA levels, a negative bone scan, and a negative CT scan, they are put on permanent androgen deprivation therapy (ADT) because the doctor just assumes it is micrometastatic. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: efficacy, high, outcome, PSA, Treatment | 2 Comments »
A new article in Frontiers in Oncology now provides us with data from the median 6-year follow-up of > 450 men with prostate cancer treated with stereotactic body radiation therapy (SBRT) using the CyberKnife technology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: body, efficacy, outcome, radiation, SBRT, stereotactic | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 